Featured

CD4 takes the lead: IL‑21 synergizes with KRAS inhibition for durable PDAC control

Pancreatic ductal adenocarcinoma (PDAC) has proven to be a challenge for immunotherapy treatment. KRAS inhibitors have shown efficacy in PDAC, but acquired resistance is common. In a recent publication in Cell, Qiang, Hoffman, Chun, et al....

ANKRD11 deficiency reprograms CD8+ T cell differentiation to enhance immunity in chronic infection and cancer

Using novel Tg mouse models, Xu et al. identified a TCR specific for a clinically relevant epitope rarely expressed on CD8+ T cells in chronic HBV infection. Efficacy of the specific TCR+ CD8+ T cells...

Antibodies against HLA-E-VL9 enhance NK cell and CD8+ T cell cytotoxicity against tumor cells and HIV-infected CD4+ T cells

Hwang et al. engineered high-affinity antibodies against HLA-E–VL9 using structure-based design and high-throughput library screening to block inhibitory NKG2A/CD94 interactions. HLA-E–VL9 mAbs enhanc...

Identification of broadly tumour-reactive γδ TCRs from multiple myeloma

St. Paul and Hendrikse et al. used single-cell sequencing and developed a machine-learning algorithm (PreGame) to distinguish the enigmatic tumor-reactive γδ T cells (TRγδ T cells) from bystander cell...

Rejuvenating endogenous antitumor immunity via a chimeric receptor-engineered oncolytic virus targeting tumor-associated macrophages

Lin et al. engineered an oncolytic herpesvirus (oHSV) with a PD-L1 nanobody attached to gD on the viral envelope surface (gDαPD- L1), targeting the virus to both tumors and TAMs expressing PD-L1. In a...

See all for this week

Previous Digests

PLA2G2D: A new checkpoint lymph node macrophage

September 23, 2026

Tumor-draining lymph nodes (tdLNs) are critical sites for both antitumor immunity and tumor metastasis. To better understand what influences these events, van Krimpen and Huang et al. performed spatial proteogenomics studies on tdLNs from patients with melanoma. In addition...

Affinity matters for novel IL-2 variant that synergizes with other immunotherapies

September 16, 2026

Antitumor IL-2 treatment comes with challenges regarding toxicity and unintended Treg activation. To overcome these challenges, various approaches to engineer IL-2 variants (IL-2var) have been developed. In a recent Science Advances publication, Vormehr et al. reported preclinical data on...

Breaking down the mechanism of enfortumab vedotin

September 9, 2026

Enfortumab vedotin (marketed under the brand name Padcev) is an approved antibody–drug conjugate (ADC) that targets Nectin-4 on cancer cells and delivers a payload of microtubule-disrupting monomethyl auristatin E (MMAE) to tumor cells. In recent work, Olson and Liu...

See More Digests

Watch ACIR in action

In November 2019, ACIR received the Visionary Award from the Cambridge Chamber of Commerce.

Watch the 3-minute video explaining ACIR's mission and goal:

In September 2020, ACIR was featured in the documentary The American Dream on Bloomberg TV.

Watch the 6-minute segment on the story behind your favorite digest here:

Donate to support researchers

About ACIR

ACIR's mission is to fast-track cancer immunotherapy research by helping researchers stay on top of the new literature in this fast-moving and multifaceted field, fostering their creativity and productivity in bringing us ever closer to curing this deadly disease.

Ute Burkhardt

Ed Fritsch

Lauren Hitchings

Gaëlle Llambi

Maartje Wouters

Alex Najibi

Katherine J. Turner

Stan Wolf

Paula Hochman

Shishir Pant

Nathan Suek

Morgan Janes

More About Us

TESTIMONIALS

I'm a big fan of ACIR. I enjoy their weekly newsletters with clear, concise, and insightful summaries, complemented by excellent images. I've even used the images in some of my presentations to explain complex cancer immunotherapy findings. In our rapidly evolving field, their reliable and well-curated updates are invaluable.

— Carl H. June, MD

Richard W. Vague Professor in Immunotherapy; Professor of PL&M; Director, Center for Cellular Immunotherapies; Director, Parker Institute for Cancer Immunotherapy; University of Pennsylvania Perelman School of Medicine. (Supporter since 2025).

Testimonials